RxDoctor Payments Data

Richard Stern, MD

Rheumatology · Dallas, TXNPI 1578562278

Payments from drug & device makers

$2,170in general payments, 2019–2025

Across 95 payments — averaging $22.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$504
  • AbbVie$413
  • Amgen$397
  • Johnson & Johnson$204
  • Aurinia Pharma U.S., Inc.$164
  • GSK$142
  • plus $346 from 8 others

What the payments were for

  • Food & beverage$2,170100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,170 in reported general payments places this provider in the 35th percentile of 512 rheumatology providers in Texas.

See all rheumatology providers in Texas

Medicare billing

Part B allowed, 2024
$56,136
Medicare patients
177
Services billed
789

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab32$262,720
RinvoqUpadacitinib27$186,905
Enbrel MiniEtanercept12$90,670
EnbrelEtanercept11$78,140
OtezlaApremilast12$65,910
Cevimeline Hcl14$5,261
MethotrexateMethotrexate Sodium139$4,940
Hydroxychloroquine Sulfate104$3,162
Mycophenolate Mofetil15$2,801
Sulfasalazine DrSulfasalazine34$1,899
Leflunomide19$1,524
Prednisone118$1,212
Allopurinol67$821
Folic Acid39$490
Leucovorin Calcium46$388

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$413$186,90527 claims
AmgenEnbrel, Otezla$397$144,05023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 512 rheumatology providers in Texas.

Other rheumatology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →